Klotho Neurosciences, Inc. (KLTO) 是一家上市公司 属于 医疗保健 板块，经营于 生物科技 行业. 公司总部位于 Omaha, NE, 美国. 现任CEO为 Joseph A. Sinkule.
KLTO 拥有 IPO日期为 2022-04-29, 3 名全职员工, 在 NASDAQ Global Market, 市值为 $20.08M.
Klotho Neurosciences, Inc., a biopharmaceutical company, develops medicines for the treatment of cancer, cardiovascular, and neurodegenerative disorders. Its lead gene therapy product candidates include AMI-101 for the treatment or prevention of Alzheimer's disease; and AMI-202 to treat and prevent amyotrophic lateral sclerosis. The company was formerly known as Anew Medical, Inc. and changed its name to Klotho Neurosciences, Inc. in September 2024. The company is based in Omaha, Nebraska.
